Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions

World health organization (WHO) (2022) Situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed September 2022 Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. Lancet 395:470–473 Huang C et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506 Vitiello A, Porta R, Pianesi L, Ferrara F (2021) COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci. https://doi.org/10.1007/s11845-021-02584-5 Li Q et al (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382:1199–1207 Zhu N et al (2019) A novel coronavirus from patients with pneumonia in China. N Engl J Med 382(2020):727–733 Gorbalenya AE et al (2020) Severe acute respiratory syndrome-related coronavirus: the species and its viruses—a statement of the Coronavirus study group. Microbiology. https://doi.org/10.1101/2020.02.07.937862 Guarner J (2020) Three emerging coronaviruses in two decades. Am J Clin Pathol 153:420–421 Vitiello A, Ferrara F (2021) Colchicine and SARS-CoV-2: management of the hyperinflammatory state. Respir Med. https://doi.org/10.1016/j.rmed.2021.106322 Vitiello A, La Porta R, D’Aiuto V, Ferrara F (2021) Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. https://doi.org/10.1016/j.humimm.2021.01.007 Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta R (2020) Cytokine storm and colchicine potential role in fighting SARS-CoV‑2 pneumonia. Ital J Med 14(2):88–94 Ferrara F, Porta R, D’Aiuto V, Vitiello A (2020) Remdesivir and COVID-19. Ir J Med Sci. https://doi.org/10.1007/s11845-020-02401-5 Jorgensen SCJ, Kebriaei R, Dresser LD (2020) Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy 40(7):659–671. https://doi.org/10.1002/phar.2429 Vitiello A, Ferrara F (2020) Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. https://doi.org/10.1007/s11845-020-02440-y Vitiello A, La Porta R, Ferrara F (2020) Sacubitril, valsartan and SARS-CoV‑2. BMJ Evid Based Med. https://doi.org/10.1136/bmjebm-2020-111497 Vitiello A, La Porta R, Trama U, Ferrara F, Zovi A, Auti AM, Di Domenico M, Boccellino M (2022) Pandemic COVID-19, an update of current status and new therapeutic strategies. Naunyn Schmiedebergs Arch Pharmacol. https://doi.org/10.1007/s00210-022-02265-9 Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A (2020) The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-coV‑2 : anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol 76(11):1615–1618. https://doi.org/10.1007/s00228-020-02947-4 Vitiello A, Pelliccia C, Ferrara F (2021) Drugs acting on the renin-angiotensin system and SARS-CoV‑2. Drug Discov Today 26(4):870–874. https://doi.org/10.1016/j.drudis.2021.01.010 Vitiello A, Ferrara F (2021) Therapeutic strategies for SARS-CoV‑2 acting on ACE‑2. Eur J Pharm Sci 156:105579. https://doi.org/10.1016/j.ejps.2020.105579 Gurwitz D (2020) Angiotensin receptor blockers as tentative SARSCoV‑2 therapeutics. Drug Dev Res 81:537–540 Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H (2004) Tissue distribution of ACE‑2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203(2):631–637 Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (2020) Angiotensin-converting enzyme 2 (ACE-2) as a SARS-CoV‑2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46:586–590 Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M et al (2012) ACE‑2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487(7408):477–481 Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, Dimitrov DS (2003) The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 312:1159–1164 Li F, Li W, Farzan M, Harrison SC (2005) Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309:1864–1868 Verdecchia P, Reboldi G, Cavallini C, Mazzotta G, Angeli F (2020) ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus. G Ital Cardiol 21(5):321–327. https://doi.org/10.1714/3343.331227 Vitiello A, Ferrara F (2021) Colchicine and SARS-CoV-2: Management of the hyperinflammatory state. Respir Med. https://doi.org/10.1016/j.rmed.2021.106322 Satou R, Penrose H, Navar G (2018) Inflammation as a regulator of the renin-angiotensin system and blood pressure. Curr Hypertens Rep. https://doi.org/10.1007/s11906-018-0900-0 Ferrara F, Vitiello A (2020) Potential pharmacological approach in the regulation of ACE‑2 and DPP-IV in diabetic COVID-19 patient. Ital J Med. https://doi.org/10.4081/itjm.2020.1435 Vitiello A, La Porta R, Ferrara F (2021) Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses 147:110486. https://doi.org/10.1016/j.mehy.2021.110486 Paz Ocaranza M, Riquelme JA, García L, Jalil JE, Chiong M, Santos RAS, Lavandero S (2020) Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol 17(2):116–129. https://doi.org/10.1038/s41569-019-0244-8 Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD (2020) Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 382(17):1653–1659. https://doi.org/10.1056/NEJMsr2005760 Vitiello A, Ferrara F (2020) Correlation between renin-angiotensin system and severe acute respiratory syndrome Coronavirus 2 infection: what do we know? Eur J Pharmacol 883:173373. https://doi.org/10.1016/j.ejphar.2020.173373 Vitiello A, Ferrara F (2020) Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci 262:118510. https://doi.org/10.1016/j.lfs.2020.118510 Imai Y, Kuba K, Penninger JM (2007) Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Cell Mol Life Sci 64(15):2006–2012 Muslim S, Nasrin N, Alotaibi FO, Prasad G, Singh SK, Alam I, Mustafa G (2020) Treatment options available for COVID-19 and an analysis on possible role of combination of rhACE‑2, angiotensin (1–7) and angiotensin (1–9) as effective therapeutic measure. SN Compr Clin Med. https://doi.org/10.1007/s42399-020-00407-9 Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM (2020) Inhibition of SARS-CoV‑2 infections in engineered human tissues using clinical-grade soluble human ACE‑2. Cell 181(4):905–913.e7. https://doi.org/10.1016/j.cell.2020.04.004 Monteil V, Dyczynski M, Lauschke VM, Kwon H, Wirnsberger G, Youhanna S, Zhang H, Slutsky AS, Hurtado Del Pozo C, Horn M, Montserrat N, Penninger JM, Mirazimi A (2021) Human soluble ACE‑2 improves the effect of remdesivir in SARS-CoV‑2 infection. EMBO Mol Med 13(1):e13426. https://doi.org/10.15252/emmm.202013426 Vitiello A, Ferrara F, La Porta R (2021) Remdesivir and COVID-19 disease, therapeutic benefitsor unnecessary risks? Ir J Med Sci 190(4):1637–1638 Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A, Madhavan MV, Nair N, Babalyan V, Hutchings N, Napoli N, Accili D, Binkley N, Landry DW, Giustina A (2020) Mechanisms in endocrinology: vitamin D and COVID-19. Eur J Endocrinol 183(5):R133–R147. https://doi.org/10.1530/EJE-20-0665 Marquez A, Wysocki J, Pandit J, Batlle D (2021) An update on ACE‑2 amplification and its therapeutic potential. Acta Physiol (Oxf) 231(1):e13513. https://doi.org/10.1111/apha.13513 Dutta K (2022) Allosteric site of ACE‑2 as a drug target for COVID-19. ACS Pharmacol Transl Sci 5:179–182 Huang L, Chen Z, Ni L, Chen L, Zhou C, Gao C, Wu X, Hua L, Huang X, Cui X et al (2021) Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the inflammatory response and viral clearance in COVID-19 patients. Front Cardiovasc Med 8:710946